Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VET3-TGI
- Development stage
- Phase 1
- Lead developer
- KaliVir Immunotherapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intravesical
01
Overview
VET3-TGI is a novel oncolytic immunotherapy developed by KaliVir Immunotherapeutics. It utilizes a genetically engineered vaccinia virus platform (Vaccinia Enhanced Template, or VET) to selectively infect and kill tumor cells. The virus delivers an immuno-stimulatory payload consisting of interleukin-12 (IL-12) and a transforming growth factor beta (TGF-β) inhibitor. Modifications for the expression of CXCR3 enhance trafficking to tumors and promote anti-tumor immune responses. It is currently being evaluated in Phase 1/1b clinical trials for advanced solid tumors as both monotherapy and in combination with checkpoint inhibitors.
02
Targets
IL-12R (Interleukin-12 receptor)CCR3 (C-C chemokine receptor type 3)IL12 (Interleukin-12)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on VET3-TGI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VET3-TGI.